SCNLF (Scancell Holdings) Total Assets: $20.53 Mil (As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Total Assets?

Scancell Holdings SCNLF 20 Total Assets is $20.53 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Scancell Holdings's Total Assets for the quarter that ended in Oct. 2025 was $20.53 Mil.

During the past 12 months, Scancell Holdings's average Total Assets Growth Rate was -9.30% per year. During the past 3 years, the average Total Assets Growth Rate was -1.00% per year. During the past 5 years, the average Total Assets Growth Rate was 3.50% per year. During the past 10 years, the average Total Assets Growth Rate was 6.90% per year.

During the past 13 years, Scancell Holdings's highest 3-Year average Total Assets Growth Rate was 22.40%. The lowest was -1.50%. And the median was 2.90%.

Total Assets is connected with ROA %. Scancell Holdings's annualized ROA % for the quarter that ended in Oct. 2025 was -60.28%. Total Assets is also linked to Revenue through Asset Turnover. Scancell Holdings's Asset Turnover for the quarter that ended in Oct. 2025 was 0.00.


Scancell Holdings  (OTCPK:SCNLF) Total Assets Explanation

Total Assets is connected with ROA %.

Scancell Holdings's annualized ROA % for the quarter that ended in Oct. 2025 is

ROA %=Net Income (Q: Oct. 2025 )/( (Total Assets (Q: Apr. 2025 )+Total Assets (Q: Oct. 2025 ))/ count )
=-15.332/( (30.342+20.53)/ 2 )
=-15.332/25.436
=-60.28 %

Note: The Net Income data used here is two times the semi-annual (Oct. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Scancell Holdings's Asset Turnover for the quarter that ended in Oct. 2025 is

Asset Turnover
=Revenue (Q: Oct. 2025 )/( (Total Assets (Q: Apr. 2025 )+Total Assets (Q: Oct. 2025 ))/ count )
=0/( (30.342+20.53)/ 2 )
=0/25.436
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Scancell Holdings Total Assets Related Terms


Scancell Holdings Total Assets Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Total Assets Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.95 45.42 33.44 29.51 30.34

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.10 29.51 21.65 30.34 20.53
SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Scancell Holdings's Total Assets for the fiscal year that ended in Apr. 2025 is calculated as

Total Assets=Total Equity (A: Apr. 2025 )+Total Liabilities (A: Apr. 2025 )
=-5.039+35.381
=30.34

Scancell Holdings's Total Assets for the quarter that ended in Oct. 2025 is calculated as

Total Assets=Total Equity (Q: Oct. 2025 )+Total Liabilities (Q: Oct. 2025 )
=-11.178+31.708
=20.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $20.53 Mil mean?
Scancell Holdings (SCNLF) has a Total Assets of $20.53 Mil as of Oct. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Scancell Holdings and its competitors.
Is Scancell Holdings' Total Assets too high?
Scancell Holdings' current Total Assets is $20.53 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Total Assets compare to VRTX and REGN?
Scancell Holdings' Total Assets of $20.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Total Assets is $20.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Total Assets of $20.53 Mil. The current Total Assets is $20.53 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Total Assets is $20.53 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price